Compare Duke Energy Corp (DUK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Novo Nordisk A/S — how do they compare? Duke Energy Corp trades at $123.39 (market cap $96.05B), while Novo Nordisk A/S trades at $46.24 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.2× Duke Energy Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| DUK | NVO | |
|---|---|---|
Market Cap | $96.05B | $207.85B |
Sector | Utilities | Health |
52-Week High | $133.46 | $63.98 |
52-Week Low | $113.99 | $35.29 |
Enterprise Value | $188.56B | $222.55B |
Dividend Yield | 3.52% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $122.97, up 1.46% today, with a bearish technical signal but strong fundamentals. Recent earnings beat estimates for three consecutive quarters, with Q2 2026 EPS at $1.43 versus $1.30 expected. The company maintains solid profitability, with a net income margin of 15.78% and ROE of 10.01%. Cash flow trends show consistent operational strength, though investing outflows remain high due to infrastructure spending.
The outlook is mixed: analyst consensus is a Buy with a $136.17 price target, but technical indicators signal near-term caution. Key risks include regulatory scrutiny and high debt levels, while opportunities lie in data-center demand growth and dividend stability. Investors should weigh strong fundamentals against bearish technicals and macroeconomic headwinds.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
